DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Nelson DR, Cooper JN, Lalezari JP. , et al; ALLY-3 Study Team.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology 2015;
61 (04) 1127-1135
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.